Search Menu

❤Donate ✔Feedback

Home
HTB
2017
November
24

HTB homepage • Conference reports • Articles by subject • Subscribe

24 November 2017

Contents

Antiretrovirals

Coformulated dolutegravir plus rilpivirine approved in US (Juluca)

Darunavir-based single pill FDC approved in EU (Symtuza)

HTB homepage • Conference reports • Articles by subject • Subscribe

This website sets no cookies from us or anyone else.

Information on this website is provided by treatment advocates and offered as a guide only. Decisions about your treatment should always be taken in consultation with your doctor.

HIV i-BASE
About us - Contact - Cookies and privacy - Copyright waiver - Terms of use - Site map - Home
Registered charity number: 1081905. Company number: 3962064.

Site navigation

i-Base: Feedback; Donate; Order and subscribe; About us; Contact

Advice and information: HIV positive – start here; Q and A; HIV treatment; HCV treatment; Pregnancy and HIV; PrEP; HIV meds; HIV testing and transmission; Guides index

News and reports: HTB – research reports and treatment access; News and updates

Other resources: Publications; Translations; Slide sets; Training manual; Glossary; Other resources